Delcath Systems Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Delcath Systems stock.
View analyst ratings for Delcath Systems or view top-rated stocks.

Wall Street analysts have given Delcath Systems a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Delcath Systems wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Delcath Systems is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for Delcath Systems.

Delcath Systems, Inc. (NASDAQ:DCTH) issued its quarterly earnings results on Wednesday, November, 11th. The company reported ($1.16) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.63) by $0.47. The firm had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.40 million.
View Delcath Systems' earnings history.

Delcath Systems' stock was trading at $9.20 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DCTH shares have increased by 94.7% and is now trading at $17.91.
View which stocks have been most impacted by COVID-19.

Shares of Delcath Systems reverse split on the morning of Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 21st 2019. An investor that had 100 shares of Delcath Systems stock prior to the reverse split would have 1 shares after the split.

3 brokerages have issued 12-month target prices for Delcath Systems' stock. Their forecasts range from $19.00 to $23.00. On average, they anticipate Delcath Systems' stock price to reach $20.67 in the next twelve months. This suggests a possible upside of 15.4% from the stock's current price.
View analysts' price targets for Delcath Systems or view top-rated stocks among Wall Street analysts.

Some companies that are related to Delcath Systems include IRadimed (IRMD), Soliton (SOLY), PAVmed (PAVM), Neuronetics (STIM), T2 Biosystems (TTOO), TELA Bio (TELA), RenovaCare (RCAR), Titan Medical (TMDI), DarioHealth (DRIO), PolyPid (PYPD), Lyra Therapeutics (LYRA), Repro Med Systems (KRMD), Nemaura Medical (NMRD), Apollo Endosurgery (APEN) and Repro-Med Systems (REPR).
View all of DCTH's competitors.

Delcath Systems trades on the NASDAQ under the ticker symbol "DCTH."

Delcath Systems' stock is owned by many different retail and institutional investors. Top institutional shareholders include Silverarc Capital Management LLC (8.54%), Ikarian Capital LLC (2.74%), Renaissance Technologies LLC (2.46%), AWM Investment Company Inc. (2.11%), Pura Vida Investments LLC (1.58%) and Alyeska Investment Group L.P. (1.20%). Company insiders that own Delcath Systems stock include Gerard J Michel, Gil Aharon and Steven A J Salamon.
View institutional ownership trends for Delcath Systems.

DCTH stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC.
View insider buying and selling activity for Delcath Systems or view top insider-selling stocks.

DCTH stock was purchased by a variety of institutional investors in the last quarter, including Silverarc Capital Management LLC, Renaissance Technologies LLC, AWM Investment Company Inc., Pura Vida Investments LLC, Alyeska Investment Group L.P., Alyeska Investment Group L.P., Verition Fund Management LLC, and Ikarian Capital LLC. Company insiders that have bought Delcath Systems stock in the last two years include Gerard J Michel, Gil Aharon, and Steven A J Salamon.
View insider buying and selling activity for Delcath Systems or or view top insider-buying stocks.

Shares of DCTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DCTH stock can currently be purchased for approximately $17.91.

Delcath Systems has a market capitalization of $73.74 million and generates $1.58 million in revenue each year. The company earns $-8,880,000.00 in net income (profit) each year or ($1,047.00) on an earnings per share basis.

Delcath Systems employs 33 workers across the globe.

The official website for Delcath Systems is delcath.com.

Delcath Systems is headquartered at 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019.

Delcath Systems' mailing address is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. The company can be reached via phone at 212 489 2100 or via email at [email protected]